ESMO Congress 2023
ESMO Congress 2023
Advertisement
Katy MarshallESMO Congress 2023 | November 3, 2023
Participating patients received PERT at baseline or within 3 months of receiving first-line treatment.
Read More
Katy MarshallESMO Congress 2023 | November 3, 2023
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
Advertisement
Advertisement
Advertisement
Latest News

March 14, 2025